In vivo CRISPR screening identifies Ptpn2 as a cancer immunotherapy target

  title={In vivo CRISPR screening identifies Ptpn2 as a cancer immunotherapy target},
  author={Robert T. Manguso and Hans W. Pope and Margaret D. Zimmer and Flavian D. Brown and Kathleen B. Yates and Brian C. Miller and Natalie Collins and Kevin Bi and Martin W LaFleur and Vikram R. Juneja and Sarah A. Weiss and Jennifer Lo and David E Fisher and Diana Miao and Eliezer M. Van Allen and David E Root and Arlene H Sharpe and John G Doench and W Nicholas Haining},
Immunotherapy with PD-1 checkpoint blockade is effective in only a minority of patients with cancer, suggesting that additional treatment strategies are needed. Here we use a pooled in vivo genetic screening approach using CRISPR–Cas9 genome editing in transplantable tumours in mice treated with immunotherapy to discover previously undescribed immunotherapy targets. We tested 2,368 genes expressed by melanoma cells to identify those that synergize with or cause resistance to checkpoint blockade… CONTINUE READING
Highly Cited
This paper has 122 citations. REVIEW CITATIONS
Related Discussions
This paper has been referenced on Twitter 451 times. VIEW TWEETS


Publications citing this paper.
Showing 1-10 of 40 extracted citations

122 Citations

Citations per Year
Semantic Scholar estimates that this publication has 122 citations based on the available data.

See our FAQ for additional information.


Publications referenced by this paper.
Showing 1-10 of 36 references

Functional Genomic Characterization of Cancer Genomes.

Cold Spring Harbor symposia on quantitative biology • 2016

regulating JAK–STAT signaling, controlling lymphoid malignancies

K. A. Pike, Tremblay, M. L. TC-PTP, PTP1B
Cytokine 82, 52–57 • 2016

Similar Papers

Loading similar papers…